Patents by Inventor Masafumi Misaki
Masafumi Misaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240024454Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation and to a method for determining the residual formaldehyde content in a pharmaceutical composition comprising an inactivated virus.Type: ApplicationFiled: June 22, 2023Publication date: January 25, 2024Inventors: Jill A. LIVENGOOD, Holli Giebler, Hansi Dean, Tatsuki Satou, Raman Rao, Jackie Marks, Mark Lyons, Asae Shintani, James Gifford, Nao Ogasawara, Masafumi Misaki, Satoshi Adachi, Sushma Kommareddy
-
Publication number: 20210403879Abstract: The present disclosure relates to methods for inactivating a Zika virus which can be used in vaccines and immunogenic compositions. The present disclosure also relates to a method for determining the completeness of inactivation of an arbovirus preparation and to a method for determining the residual formaldehyde content in a pharmaceutical composition comprising an inactivated virus.Type: ApplicationFiled: November 30, 2018Publication date: December 30, 2021Inventors: Jill A LIVENGOOD, Holli GIEBLER, Hansi DEAN, Tatsuki SATOU, Raman RAO, Jackie MARKS, Mark LYONS, Asae SHINTANI, James GIFFORD, Nao OGASAWARA, Masafumi MISAKI, Satoshi ADACHI
-
Publication number: 20190054026Abstract: The present invention provides a solid preparation wherein variation in weight is suppressed, a solid preparation wherein the active ingredient is stabilized, and a stabilization method thereof. A solid preparation containing (1) an active ingredient, (2) D-mannitol and (3) an alkaline earth metal salt selected from magnesium aluminometasilicate and calcium silicate. A method of stabilizing the active ingredient, including adding an alkaline earth metal salt selected from magnesium aluminometasilicate and calcium silicate.Type: ApplicationFiled: March 20, 2018Publication date: February 21, 2019Inventors: Wataru Hoshina, Masafumi Misaki
-
Patent number: 9757377Abstract: The present invention provides a solid preparation excellent in disintegration property and preservation stability. The present invention relates to a solid preparation containing (1) 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile (compound (A)) or a salt thereof, (2) a saccharide, and (3) sodium stearyl fumarate. In addition, the present invention relates to a solid preparation containing (1) compound (A) or a salt thereof, (2) a saccharide, and (3) stearic acid or talc in a naked tablet part.Type: GrantFiled: September 22, 2016Date of Patent: September 12, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Maiko Harada, Ikurou Yamane, Masafumi Misaki
-
Publication number: 20170202777Abstract: The present invention provides a solid preparation wherein variation in weight is suppressed, a solid preparation wherein the active ingredient is stabilized, and a stabilization method thereof. A solid preparation containing (1) an active ingredient, (2) D-mannitol and (3) an alkaline earth metal salt selected from magnesium aluminometasilicate and calcium silicate. A method of stabilizing the active ingredient, including adding an alkaline earth metal salt selected from magnesium aluminometasilicate and calcium silicate.Type: ApplicationFiled: August 24, 2016Publication date: July 20, 2017Inventors: Wataru Hoshina, Masafumi Misaki
-
Publication number: 20170007607Abstract: The present invention provides a solid preparation excellent in disintegration property and preservation stability. The present invention relates to a solid preparation containing (1) 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile (compound (A)) or a salt thereof, (2) a saccharide, and (3) sodium stearyl fumarate. In addition, the present invention relates to a solid preparation containing (1) compound (A) or a salt thereof, (2) a saccharide, and (3) stearic acid or talc in a naked tablet part.Type: ApplicationFiled: September 22, 2016Publication date: January 12, 2017Applicant: Takeda Pharmaceutical Company LimitedInventors: Maiko Harada, Ikurou Yamane, Masafumi Misaki
-
Patent number: 9486411Abstract: The present invention provides a solid preparation excellent in disintegration property and preservation stability. The present invention relates to a solid preparation containing (1) 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile (compound (A)) or a salt thereof, (2) a saccharide, and (3) sodium stearyl fumarate. In addition, the present invention relates to a solid preparation containing (1) compound (A) or a salt thereof, (2) a saccharide, and (3) stearic acid or talc in a naked tablet part.Type: GrantFiled: June 4, 2013Date of Patent: November 8, 2016Assignee: Takeda Pharmaceutical Company LimitedInventors: Maiko Harada, Ikurou Yamane, Masafumi Misaki
-
Publication number: 20150157609Abstract: The present invention provides a solid preparation wherein variation in weight is suppressed, a solid preparation wherein the active ingredient is stabilized, and a stabilization method thereof. A solid preparation containing (1) an active ingredient, (2) D-mannitol and (3) an alkaline earth metal salt selected from magnesium aluminometasilicate and calcium silicate. A method of stabilizing the. active ingredient, including adding an alkaline earth metal salt selected from magnesium aluminometasilicate and calcium silicate.Type: ApplicationFiled: March 29, 2012Publication date: June 11, 2015Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Wataru Hoshina, Masafumi Misaki
-
Publication number: 20150141447Abstract: The present invention provides a solid preparation excellent in disintegration property and preservation stability. The present invention relates to a solid preparation containing (1) 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile (compound (A)) or a salt thereof, (2) a saccharide, and (3) sodium stearyl fumarate. In addition, the present invention relates to a solid preparation containing (1) compound (A) or a salt thereof, (2) a saccharide, and (3) stearic acid or talc in a naked tablet part.Type: ApplicationFiled: June 4, 2013Publication date: May 21, 2015Applicant: Takeda Pharmaceutical Company LimitedInventors: Maiko Harada, Ikurou Yamane, Masafumi Misaki
-
Publication number: 20150110873Abstract: The present invention relates to an enteric tablet with improved bioavailability, which is rapidly disintegrated after reaching the intestine to allow dissolution of the active ingredient, and which characteristically reduces the amount of talc to be used and is free of an alkali component.Type: ApplicationFiled: December 26, 2014Publication date: April 23, 2015Inventors: Masafumi MISAKI, Yuki TSUSHIMA, Masahiro NIWA
-
Patent number: 8920840Abstract: The present invention relates to an enteric tablet with improved bioavailability, which is rapidly disintegrated after reaching the intestine to allow dissolution of the active ingredient, and which characteristically reduces the amount of talc to be used and is free of an alkali component.Type: GrantFiled: April 28, 2011Date of Patent: December 30, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Masafumi Misaki, Yuki Tsushima, Masahiro Niwa
-
Patent number: 8637077Abstract: Sustained release preparations, which show suppressed initial release of a physiologically active substance and can release a constant amount of the physiologically active substance over a long period of time, and dispersion vehicle thereof can be obtained by adding a cationic substance or polyols to the outside of a matrix or dispersion vehicle thereof. Thus, sustained release preparations, which show suppressed initial release of a physiologically active substance immediately after the administration and can release a constant amount of the physiologically active substance over a long period of time and dispersion vehicle thereof can be provided.Type: GrantFiled: December 26, 2001Date of Patent: January 28, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Shigeyuki Takada, Masafumi Misaki, Kenji Nakamura
-
Publication number: 20130115291Abstract: The present invention relates to an enteric tablet with improved bioavailability, which is rapidly disintegrated after reaching the intestine to allow dissolution of the active ingredient, and which characteristically reduces the amount of talc to be used and is free of an alkali component.Type: ApplicationFiled: April 28, 2011Publication date: May 9, 2013Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Masafumi Misaki, Yuki Tsushima, Masahiro Niwa
-
Publication number: 20130115292Abstract: The present invention relates to an enteric tablet with improved bioavailability, which is rapidly disintegrated after reaching the intestine to allow dissolution of the active ingredient, and which characteristically reduces the amount of talc to be used and is free of an alkali component.Type: ApplicationFiled: April 28, 2011Publication date: May 9, 2013Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Masafumi Misaki, Yuki Tsushima, Masahiro Niwa
-
Patent number: 8071130Abstract: The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from “a solid preparation containing only an insulin sensitizer as an active ingredient”. The solid preparation comprises “a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol” and “a part containing an active ingredient other than an insulin sensitizer”.Type: GrantFiled: December 21, 2006Date of Patent: December 6, 2011Assignee: Takeda Pharmaceutical Company LimitedInventors: Kenichiro Kiyoshima, Kenji Nakamura, Tetsuya Kawano, Masafumi Misaki
-
Publication number: 20090028939Abstract: The present invention intends to provide a solid preparation which contains an insulin sensitizer and an active ingredient other than an insulin sensitizer, and exhibits dissolution behavior of an insulin sensitizer similar to that of an insulin sensitizer from “a solid preparation containing only an insulin sensitizer as an active ingredient”. The solid preparation comprises “a part containing coated particles in which the particles containing an insulin sensitizer are coated with lactose or a sugar alcohol” and “a part containing an active ingredient other than an insulin sensitizer”.Type: ApplicationFiled: December 21, 2006Publication date: January 29, 2009Inventors: Kenichiro Kiyoshima, Kenji Nakamura, Tetsuya Kawano, Masafumi Misaki
-
Publication number: 20060280794Abstract: A solid preparation comprising an insulin sensitizer and an HMG-CoA reductase inhibitor without deteriorating the stabilities of these drugs, wherein said preparation comprises particles containing an insulin sensitizer and particles containing an HMG-CoA reductase inhibitor.Type: ApplicationFiled: June 3, 2004Publication date: December 14, 2006Inventors: Naoru Hamaguchi, Hiroyoshi Koyama, Masafumi Misaki
-
Publication number: 20060241045Abstract: A method for producing a preparation containing a bioactive substance, characterized in that it comprises forming a solid material containing the bioactive substance and a polymer, and contacting the solid material with a high pressure gas. The method allows the production of a preparation which is suppressed in excessive initial release of the bioactive substance immediately after the administration thereof, is capable of releasing a predetermined amount of the bioactive substance over a long period of time, and is extremely reduced in the deterioration of the bioactive substance and in the amount of a residual organic solvent.Type: ApplicationFiled: June 23, 2006Publication date: October 26, 2006Inventors: Yoshihiro Ohmachi, Masafumi Misaki, Shigeyuki Takada
-
Patent number: 7090869Abstract: A method for producing a preparation containing a bioactive substance, characterized in that it comprises forming a solid material containing the bioactive substance and a polymer, and contacting the solid material with a high pressure gas. The method allows the production of a preparation which is suppressed in excessive initial release of the bioactive substance immediately after the administration thereof, is capable of releasing a predetermined amount of the bioactive substance over a long period of time, and is extremely reduced in the deterioration of the bioactive substance and in the amount of a residual organic solvent.Type: GrantFiled: November 29, 2001Date of Patent: August 15, 2006Assignee: Takeda Pharmaceutical Company LimitedInventors: Yoshihiro Ohmachi, Masafumi Misaki, Shigeyuki Takada
-
Publication number: 20040057996Abstract: Sustained release preparations, which show suppressed initial release of a physiologically active substance and can release a constant amount of the physiologically active substance over a long period of time, and dispersion vehicle thereof can be obtained by adding a cationic substance or polyols to the outside of a matrix or dispersion vehicle thereof. Thus, sustained release preparations, which show suppressed initial release of a physiologically active substance immediately after the administration and can release a constant amount of the physiologically active substance over a long period of time and dispersion vehicle thereof can be provided.Type: ApplicationFiled: June 27, 2003Publication date: March 25, 2004Inventors: Shigeyuki Takada, Masafumi Misaki, Kenji Nakamura